alfuzosin

Also known as SL-77499-10, SL-7749910, Uroxatral®, (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide, Alfuzosina, N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide, Alfuzosine, Alfuzosinum

Alfuzosin, sold under the brand name Uroxatral among others, is a medication of the α1 blocker class. It is used to treat benign prostatic hyperplasia (BPH).

Key facts

Drug.H: 27
Drug.N: 5
Drug.O: 4
Drug.Watchedfields: changed
Drug.class: α1 blocker
Drug.verifiedrevid: 477247048
Drug.image: Alfuzosin.svg
Drug.image_class: skin-invert-image
Drug.width: 275
Drug.tradename: Uroxatral, others
Drug.MedlinePlus: a64002
Drug.DailyMedID: Alfuzosin
Drug.pregnancy_AU: B2

~4 min read

Article

11 sections

Contents

Clinical information
Side effects
Indications for use
Contraindications
Pharmacological properties
Chemistry
Society and culture
History
Brand names
Synthesis
References

Alfuzosin, sold under the brand name Uroxatral among others, is a medication of the α1 blocker class. It is used to treat benign prostatic hyperplasia (BPH).

As an antagonist of the α1-adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making urination easier.